Many studies have looked at the effect of PARP inhibitors on other solid tumors, as well as ovarian and breast cancer, the first shown to possess the BRCA mutations, including pancreatic and prostate cancer 38, 39. The gene discussed is PARP1; the disease is prostate cancer.